Physician profile
Brenda Reilly
NPI 1255772471
$9,032.19
in general payments reported to CMS, 2019-2025
24 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,357 · 2022: $1,368 · 2023: $2,190 · 2024: $1,855 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,028 · Education: $259 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,028.12 |
| Education | $258.53 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,031.36 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $945.87 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $904.01 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $781.91 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $772.90 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $769.97 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $768.01 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $709.04 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $509.64 | 2021-2024 | Perseris |
| Abbvie INC. | $483.64 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $383.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.32 | 2024-2025 | Cobenfy |
| Harmony Biosciences LLC | $218.84 | 2024-2025 | |
| Almatica Pharma LLC | $209.25 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $47.11 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.08 | 2024 | Auvelity |
| Livanova USA, INC. | $47.03 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Orexo US, INC. | $35.34 | 2025 | Zubsolv |
| Eisai INC. | $30.35 | 2021-2022 | |
| Noven Therapeutics, LLC | $23.13 | 2024 | Secuado |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.57 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Uswm, LLC | $16.08 | 2021 | |
| Braeburn INC. | $13.09 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.